Dr. Justin Levisay, MD
Claim this profileEvanston Hospital
Studies Myocardial Infarction
Studies Stent Restenosis
7 reported clinical trials
11 drugs studied
Affiliated Hospitals
Clinical Trials Justin Levisay, MD is currently running
Transseptal ViMAC
for Mitral Valve Disease
A prospective multicenter study enrolling high surgical risk patients with severe mitral annular calcification (MAC) and symptomatic mitral valve dysfunction (severe stenosis, ≥ moderate to severe regurgitation, or mixed ≥ moderate stenosis and ≥ regurgitation). There are 2 Arms in this study: 1) "Transseptal (TS) Valve-in-MAC" (ViMAC) Arm, and 2) Natural History of Disease Registry (NHDR) for patients treated with medical treatment only (which includes patients who meet inclusion criteria but can't be treated with transeptal ViMAC due to the presence of anatomical exclusion criteria or other exclusion criteria) and have not had other procedures that may impact outcomes (i.e., alcohol septal ablation or radiofrequency ablation). The study also includes a Registry of Permanently Unassigned" for subjects who undergo preemptive septal ablation procedures (alcohol or radiofrequency) in anticipation of continuing onto ViMAC arm, but are not accepted in the ViMAC Study arm or the patient chooses not to undergo ViMAC procedure.
Recruiting1 award N/A2 criteria
Paclitaxel-Coated Balloon Catheter
for Stent Restenosis
The purpose of the AGENT IDE study is to assess the safety and effectiveness of the Agent Paclitaxel Coated PTCA Balloon Catheter in patients with in-stent restenosis (ISR) of a previously treated lesion of up to 36 mm in length (by visual estimate) in a native coronary artery 2.0 mm to 4.0 mm in diameter.
Recruiting2 awards Phase 36 criteria
More about Justin Levisay, MD
Clinical Trial Related4 years of experience running clinical trials · Led 7 trials as a Principal Investigator · 3 Active Clinical TrialsTreatments Justin Levisay, MD has experience with
- ACURATE Neo2™ Transfemoral TAVR System
- Medtronic CoreValve TAVR System
- Edwards SAPIEN 3 TAVR System
- ACURATE Prime™ Transfemoral TAVR System XL
- Prophylactic Impella Support
- IMPELLA® CP System
Breakdown of trials Justin Levisay, MD has run
Myocardial Infarction
Stent Restenosis
Valvular Heart Disease
Mitral Regurgitation
Mitral Valve Regurgitation
Other Doctors you might be interested in
Frequently asked questions
Do I need insurance to participate in a trial?
Almost all clinical trials will cover the cost of the ‘trial drug’ — so no insurance is required for this. For trials where this trial drug is given alongside an already-approved medication, there may be a cost (which your insurance would normally cover).
What does Justin Levisay, MD specialize in?
Justin Levisay, MD focuses on Myocardial Infarction and Stent Restenosis. In particular, much of their work with Myocardial Infarction has involved treating patients, or patients who are undergoing treatment.
Is Justin Levisay, MD currently recruiting for clinical trials?
Yes, Justin Levisay, MD is currently recruiting for 3 clinical trials in Evanston Illinois. If you're interested in participating, you should apply.
Are there any treatments that Justin Levisay, MD has studied deeply?
Yes, Justin Levisay, MD has studied treatments such as ACURATE neo2™ Transfemoral TAVR System, Medtronic CoreValve TAVR System, Edwards SAPIEN 3 TAVR System.
What is the best way to schedule an appointment with Justin Levisay, MD?
Apply for one of the trials that Justin Levisay, MD is conducting.
What is the office address of Justin Levisay, MD?
The office of Justin Levisay, MD is located at: Evanston Hospital, Evanston, Illinois 60201 United States. This is the address for their practice at the Evanston Hospital.
Is there any support for travel costs?
The coverage of travel expenses can vary greatly between different clinical trials. Please see more financial detail in the trials you’re interested to apply.